HEIDELBERG, Germany, Sept. 18 /PRNewswire/ -- TEMIS, leading provider of Text Analytics software solutions for the Life Science industry announced today that they have entered in a strategic software and services agreement with Bayer HealthCare. Bayer HealthCare has chosen TEMIS acclaimed Text Analytics solution to streamline and speed up its drug discovery process.
Efficient information management is a major challenge in biological, chemical and clinical research today. However, a large part of the critical information is only available from scientific articles and patent documents that are stored in free text format. This volume of literature is growing exponentially and makes it almost impossible for researchers and scientists to retrieve all relevant information on a specific topic and keep up with current research. Bayer HealthCare’s scientists required a powerful system able to integrate information from various sources and across different disciplines.
With Luxid(R) for Life Sciences, TEMIS brings a long-awaited answer to the challenges of unstructured information management through automated domain- specific knowledge extraction, flexible analytics, documents classification, relationships representation and retrieval capabilities. Luxid(R) for Life Sciences’ specific Skill Cartridges(TM) dedicated to the fields of biology, chemistry and medicine, provide Bayer HealthCare Information Professionals with instant access to powerful text analytics capabilities, supporting their efforts all along the product lifecycle, from target identification and lead compound selection to safety assessment.
What makes Luxid(R) for Life Sciences really special for Bayer HealthCare is its ability to analyze various kind of information within one single application. Most applications in this field concentrate on just one knowledge area like protein-protein interaction, but TEMIS has created a powerful integrated solution which allows to analyze chemical information together with biological information for example.
“We are delighted with this renewed trust from our much valued customer,” said Guillaume Mazieres, VP Sales & Marketing of TEMIS. “It proves that our Life Science dedicated solution addresses the very specific needs of drug discovery. We are proud to support Bayer HealthCare’s research activity by delivering actionable and targeted knowledge to their Information Professionals.”
Bayer HealthCare will now provide an unlimited web access to Luxid(R) for Life Sciences to a strategic internal team of information professionals. This expert team already acquainted to information retrieval technologies will now use Luxid(R) for Life Sciences to conduct focused studies based on scientific literature and patents requested by internal customers from chemical or biological research, drug life cycle management or IP departments.
Bayer HealthCare chose to integrate Luxid(R) for Life Sciences into its scientific intelligence process as it bridges three critical research areas (Chemistry, Biology and Medicine), to help unveil new indications for known drugs, new molecular entities for known targets or even new targets for selected indications.
About TEMIS
Founded in 2000, TEMIS is a leading provider of Corporate Text Mining and Text Analytics software solutions. TEMIS addresses the unstructured data management needs of Corporations (Life Sciences, Publishing, Industry) and Governments, in environments where information processing is critical such as Competitive Intelligence, CRM, Scientific Intelligence, IP Management or Quality Management. TEMIS solutions help thousands of users everyday gain immediate access to business critical information, using concepts and meaning extraction, automatic classification and relationship representation, in order to reduce information overload.
TEMIS employs about 50 people and operates subsidiaries in France, Germany, and the United States. TEMIS team brings together skilled and experienced managers, researchers and consultants. TEMIS products are distributed worldwide through its partner network.
From the very beginning, TEMIS’ innovative technology has attracted major groups such as Thomson Scientific, Springer Science+Business Media, MDL Elsevier, TIM-Telecom Italia Mobile, Novartis, Roche, Sanofi-Aventis, Solvay Pharmaceuticals, PSA Peugeot-Citroen, or Total.
TEMIS won the 2007 European Information and Communications Technology Prize with Luxid(R) Information Intelligence solution.
TEMIS
CONTACT: TEMIS, Martine Falhon, Corporate Communications, +33-456-382-403,martine.falhon@temis.com
Web site: http://www.temis.com/
